AstraZeneca: CHMP recommends Imfinzi and Lynparza
Imfinzi + chemotherapy as first-line treatment, followed by Lynparza and Imfinzi has been recommended for patients with mismatch repair disease (pMMR).
Imfinzi + chemotherapy followed by Imfinzi alone has been recommended for patients with mismatch repair deficient disease (dMMR).
The CHMP relies on an analysis from a phase III trial published in the Journal of Clinical Oncology in October 2023.
This analysis showed a 43% reduction in the risk of disease progression or death for pMMR patients in the Lynparza and Imfinzip arm compared with the control arm, and a 58% reduction for dMMR patients in the Imfinzi arm compared with the control arm.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction